This content is for informational purposes only and is not a substitute for professional advice.
"Crosses the blood-brain barrier" is a pharmacology statement, not a finished proof of benefit. It belongs in regulatory categories analysis because supplement marketing often turns delivery language into outcome language.
Decision criteria
This guide separates four questions: can the molecule reach the brain, does it reach meaningful concentrations, does that change a human outcome, and is the risk acceptable.
| Claim type | Better evidence | Weak evidence |
|---|---|---|
| Brain entry | Human pharmacokinetics or imaging | Animal-only marketing |
| Mechanism | Dose-relevant human biomarker | Cell study at unrealistic concentration |
| Outcome | RCT with cognitive endpoint | "Supports neurons" copy |
| Safety | Medication and condition cautions | "Natural and safe" |
Common examples
L-theanine, caffeine, nicotine, some choline forms, and certain drugs clearly affect the brain. That does not mean every brain-active compound is a good idea. More brain entry can mean more side effects.
Magnesium threonate is marketed around brain magnesium delivery, though human cognitive claims remain much more limited than the branding suggests. Lion's mane is often framed through nerve-growth mechanisms, yet human trials remain early. Curcumin has brain-health marketing, yet bioavailability and clinical outcome questions remain separate.
Practical audit
| Product question | Pass |
|---|---|
| Does the label name the active form? | Yes, with dose |
| Are studies on the same form? | Yes, not a related compound |
| Is the endpoint human and relevant? | Memory, attention, sleep, or fatigue measured directly |
| Are risks named? | Medication, pregnancy, psychiatric, liver, bleeding cautions |
Disclosure
Unfair does not rate a supplement higher only because a brand says it crosses the blood-brain barrier. In Unfair, brain-delivery claims should be treated as mechanism notes and weighed against outcomes, adverse effects, and risk checks.
References
Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4292164/
↩Dodd FL, et al. Caffeine and L-theanine study. https://pubmed.ncbi.nlm.nih.gov/25761845/
↩Federal Trade Commission. Health Products Compliance Guidance. https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance
↩